TY  - JOUR
AU  - Morales-Cano, Daniel
AU  - Izquierdo-García, Jose Luis
AU  - Barreira, Bianca
AU  - Esquivel-Ruiz, Sergio
AU  - Callejo, Maria
AU  - Pandolfi, Rachele
AU  - Villa-Valverde, Palmira
AU  - Rodríguez, Ignacio
AU  - Cogolludo, Angel
AU  - Ruiz-Cabello, Jesus
AU  - Perez-Vizcaino, Francisco
AU  - Moreno, Laura
PY  - 2023
DO  - 10.3389/fphar.2023.1021535
SN  - 1663-9812
UR  - http://hdl.handle.net/20.500.12105/16256
AB  - Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH...
LA  - eng
PB  - Frontiers Media
TI  - Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
TY  - journal article
ER  -